6-(5-(1-cyclopropyl-6-oxo-1,6-dihydro-pyridazin-3-yl)-4,5-dihydroisoxazol-3-yl)-N-(4-fluoro-3-methoxybenzyl)-2-methylpyrimidine-4-carboxamide | 1408332-13-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 三唑并嘧啶类
• 英文名称: 6-(5-(1-cyclopropyl-6-oxo-1,6-dihydro-pyridazin-3-yl)-4,5-dihydroisoxazol-3-yl)-N-(4-fluoro-3-methoxybenzyl)-2-methylpyrimidine-4-carboxamide
• 英文别名: 6-[5-(1-cyclopropyl-6-oxopyridazin-3-yl)-4,5-dihydro-1,2-oxazol-3-yl]-N-[(4-fluoro-3-methoxyphenyl)methyl]-2-methylpyrimidine-4-carboxamide
• CAS: 1408332-13-7
• 化学式: C₂₄H₂₃FN₆O₄
• 分子量: 478.483
• InChiKey: BSUOXCWNKFVSGN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  35
• 可旋转键数：
  7
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  118
• 氢给体数：
  1
• 氢受体数：
  9

文献信息

• Isoxazolines as Therapeutic Agents
  申请人：Calderwood David J.

  公开号：US20130023526A1

  公开（公告）日：2013-01-24

  The present invention provides compound of Formula (I) biologically active metabolites, pro-drugs, isomers, stereoisomers, solvates, hydrates and pharmaceutically acceptable salts thereof wherein the variables are defined herein. The compounds of the invention are useful for treating immunological conditions.

  本发明提供了化合物Formula（I）的生物活性代谢产物、前药、异构体、立体异构体、溶剂合物、水合物和其药学上可接受的盐，其中变量在此处定义。本发明的化合物对治疗免疫状况有用。
• ISOXAZOLINES AS THERAPEUTIC AGENTS
  申请人：ABBVIE INC.

  公开号：US20150297596A1

  公开（公告）日：2015-10-22

  The present invention provides compound of Formula (I) biologically active metabolites, pro-drugs, isomers, stereoisomers, solvates, hydrates and pharmaceutically acceptable salts thereof wherein the variables are defined herein. The compounds of the invention are useful for treating immunological conditions.

  本发明提供了化合物式（I）的生物活性代谢物、前药、异构体、立体异构体、溶剂化物、水合物及其药学上可接受的盐，其中变量如本文所定义。本发明化合物用于治疗免疫疾病。
• US9029409B2
  申请人：——

  公开号：US9029409B2

  公开（公告）日：2015-05-12
• [EN] ISOXAZOLINES AS THERAPEUTIC AGENTS<br/>[FR] ISOXAZOLINES UTILISÉES EN TANT QU'AGENTS THÉRAPEUTIQUES
  申请人：ABBOTT LAB

  公开号：WO2012151158A1

  公开（公告）日：2012-11-08

  The present invention provides compound of Formula (1) biologically active metabolites, pro-drugs, isomers, stereoisomers, solvates, hydrates and pharmaceutically acceptable salts thereof wherein the variables are defined herein. The compounds of the invention are useful for treating immunological conditions. X is an optionally substituted ring system which is aromatic, partly aromatic or non-aromatic having one or more fused ring systems.